Matthias Kroiss

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6045937/publications.pdf

Version: 2024-02-01

92 papers	6,682 citations	81900 39 h-index	64796 79 g-index
95 all docs	95 docs citations	95 times ranked	5950 citing authors

#	Article	IF	Citations
1	Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e865-e873.	3.6	7
2	S-GRAS score for prognostic classification of adrenocortical carcinoma: an international, multicenter ENSAT study. European Journal of Endocrinology, 2022, 186, 25-36.	3.7	41
3	Treatment of RET-Positive Advanced Medullary Thyroid Cancer with Multi-Tyrosine Kinase Inhibitorsâ€"A Retrospective Multi-Center Registry Analysis. Cancers, 2022, 14, 3405.	3.7	4
4	PKA CÎ± subunit mutation triggers caspase-dependent RIIÎ² subunit degradation via Ser ¹¹⁴ phosphorylation. Science Advances, 2021, 7, .	10.3	4
5	Steroid Sulfation in Adrenal Tumors. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 3385-3397.	3.6	4
6	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. Clinical Chemistry, 2021, 67, 998-1007.	3.2	18
7	Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. Cancer Discovery, 2021, 11, 2780-2795.	9.4	125
8	The role of regulated necrosis in endocrine diseases. Nature Reviews Endocrinology, 2021, 17, 497-510.	9.6	35
9	High expression of Sterol-O-Acyl transferase 1 (SOAT1), an enzyme involved in cholesterol metabolism, is associated with earlier biochemical recurrence in high risk prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	10
10	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	3.6	19
11	A Micellar Mitotane Formulation with High Drugâ€Loading and Solubility: Physicoâ€Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models. Macromolecular Bioscience, 2020, 20, e1900178.	4.1	14
12	Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1461-1468.	3.6	39
13	Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. New England Journal of Medicine, 2020, 383, 825-835.	27.0	454
14	The landscape of chromothripsis across adult cancer types. Nature Communications, 2020, 11, 2320.	12.8	75
15	Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. , 2020, 8, e000469.		59
16	Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction. Cell Death and Disease, 2020, 11, 192.	6.3	39
17	Effects of Germline CYP2W1*6 and CYP2B6*6 Single Nucleotide Polymorphisms on Mitotane Treatment in Adrenocortical Carcinoma: A Multicenter ENSAT Study. Cancers, 2020, 12, 359.	3.7	23
18	Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2239-e2246.	3.6	10

#	Article	IF	Citations
19	Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2642-2653.	3.6	18
20	Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma. Genetics in Medicine, 2019, 21, 705-717.	2.4	60
21	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	7.1	57
22	Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22269-22274.	7.1	81
23	Prognostic Relevance of Steroid Sulfation in Adrenocortical Carcinoma Revealed by Molecular Phenotyping Using High-Resolution Mass Spectrometry Imaging. Clinical Chemistry, 2019, 65, 1276-1286.	3.2	19
24	A method for the minimally invasive drug monitoring of mitotane by means of volumetric absorptive microsampling for a home-based therapeutic drug monitoring. Analytical and Bioanalytical Chemistry, 2019, 411, 3951-3962.	3.7	14
25	Volumetric and texture analysis of pretherapeutic 18F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib. Endocrine, 2019, 63, 293-300.	2.3	13
26	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Annals of Surgical Oncology, 2019, 26, 531-538.	1.5	22
27	Advanced Adrenocortical Carcinoma â€“ What to do when First-Line Therapy Fails?. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 109-116.	1.2	43
28	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 578-584.	1.2	15
29	Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. Molecular and Cellular Endocrinology, 2019, 480, 36-41.	3.2	8
30	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. European Journal of Endocrinology, 2019, 180, 117-125.	3.7	59
31	Objective response and prolonged stable disease in refractory adrenocortical carcinoma treated with cabozantinib: An international case series and protocols of phase II clinical trials.. Journal of Clinical Oncology, 2019, 37, e16118-e16118.	1.6	0
32	Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1686-1695.	3.6	105
33	High-Resolution Tissue Mass Spectrometry Imaging Reveals a Refined Functional Anatomy of the Human Adult Adrenal Gland. Endocrinology, 2018, 159, 1511-1524.	2.8	37
34	Predictive Value of ¹⁸F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib. Journal of Nuclear Medicine, 2018, 59, 756-761.	5.0	26
35	Targeted Molecular Analysis in Adrenocortical Carcinomas: A Strategy Toward Improved Personalized Prognostication. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 4511-4523.	3.6	92
36	Abiraterone Acetate for Cushing Syndrome: Study in a Canine Primary Adrenocortical Cell Culture Model. Endocrinology, 2018, 159, 3689-3698.	2.8	4

#	Article	IF	Citations
37	A Copeptin-Based Approach in the Diagnosis of Diabetes Insipidus. New England Journal of Medicine, 2018, 379, 428-439.	27.0	180
38	Enzyme autoinduction by mitotane supported by population pharmacokinetic modeling in a large cohort of adrenocortical carcinoma patients. European Journal of Endocrinology, 2018, 179, 287-297.	3.7	15
39	FGF-21 levels in polyuria-polydipsia syndrome. Endocrine Connections, 2018, 7, 1501-1506.	1.9	0
40	Investigating the Chemokine Receptor 4 as Potential Theranostic Target in Adrenocortical Cancer Patients. Clinical Nuclear Medicine, 2017, 42, e29-e34.	1.3	60
41	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. European Journal of Endocrinology, 2017, 177, 227-237.	3.7	23
42	Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codonâ€specific penetrance and changes in management during the last four decades. Clinical Endocrinology, 2017, 87, 320-326.	2.4	32
43	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	3.6	79
44	Functional Implications of LH/hCG Receptors in Pregnancy-Induced Cushing Syndrome. Journal of the Endocrine Society, 2017, 1, 57-71.	0.2	20
45	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. BMC Cancer, 2017, 17, 522.	2.6	29
46	Inhibition of Cholesterol Esterification in the Adrenal Gland by ATR101/PD132301â€“2, A Promising Case of Drug Repurposing. Endocrinology, 2016, 157, 1719-1721.	2.8	5
47	DNA methylation is an independent prognostic marker of survival in adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3205.	3.6	44
48	Assessment of tumor heterogeneity in treatment-naÃ¯ve adrenocortical cancer patients using 18F-FDG positron emission tomography. Endocrine, 2016, 53, 791-800.	2.3	8
49	Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. Hormones and Cancer, 2016, 7, 345-355.	4.9	12
50	Clinical presentation, treatment and outcome of anaplastic thyroid carcinoma: results of a multicenter study in Germany. European Journal of Endocrinology, 2016, 175, 521-529.	3.7	90
51	The adrenal specific toxicant mitotane directly interacts with lipid membranes and alters membrane properties depending on lipid composition. Molecular and Cellular Endocrinology, 2016, 428, 68-81.	3.2	25
52	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. Hormones and Cancer, 2016, 7, 211-218.	4.9	16
53	Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. European Journal of Endocrinology, 2016, 174, 343-353.	3.7	20
54	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	3.6	274

#	Article	IF	Citations
55	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
56	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncology, The, 2015, 16, 426-435.	10.7	272
57	Prognostic factors in stage IIIâ€“IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Annals of Oncology, 2015, 26, 2119-2125.	1.2	196
58	Notch1 pathway in adrenocortical carcinomas: correlations with clinical outcome. Endocrine-Related Cancer, 2015, 22, 531-543.	3.1	27
59	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	2.8	153
60	ATR-101 phase 1 clinical study for adrenocortical carcinoma.. Journal of Clinical Oncology, 2015, 33, TPS4585-TPS4585.	1.6	3
61	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	2.5	41
62	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. European Journal of Endocrinology, 2014, 171, R1-R11.	3.7	37
63	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	1.9	121
64	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560
65	No endogenous ouabain is detectable in human plasma by ultra-sensitive UPLC-MS/MS. Clinica Chimica Acta, 2014, 431, 87-92.	1.1	58
66	Thyroid Function, Cardiovascular Events, and Mortality in Diabetic Hemodialysis Patients. American Journal of Kidney Diseases, 2014, 63, 988-996.	1.9	57
67	Mitotane induces endoplasmic reticulum stress triggering apoptosis and decrease of steroid hormone synthesis. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	1
68	Transient pregnancy-induced Cushing's Syndrome with Aberrant Adrenal hCG receptor. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	1
69	Expression of CYP2W1 in the adrenal gland: relationship with hormone secretion and clinical outcome. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
70	Treatment of refractory adrenocortical carcinoma with thalidomide: results of a retrospective analysis of 15 patients. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
71	Towards a registry for rare malignant tumors of the thyroid. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, .	1.2	0
72	Prognostic factors of overall survival of stage III or IV adrenocortical carcinomas (ACC): A multicenter ENS@T study.. Journal of Clinical Oncology, 2014, 32, 4106-4106.	1.6	0

#	Article	IF	Citations
73	Update in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4551-4564.	3.6	346
74	Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatographytandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma. Annals of Clinical Biochemistry, 2013, 50, 147-155.	1.6	99
75	Prognostic impact of subclinical thyroid dysfunction in heart failure. International Journal of Cardiology, 2013, 168, 300-305.	1.7	57
76	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 181-191.	3.6	132
77	Survivin in Adrenocortical Tumors - Pathophysiological Implications and Therapeutic Potential. Hormone and Metabolic Research, 2013, 45, 137-146.	1.5	19
78	Is There a Role for Laparoscopic Adrenalectomy in Patients with Suspected Adrenocortical Carcinoma? A Critical Appraisal of the Literature. Hormone and Metabolic Research, 2013, 45, 130-136.	1.5	27
79	Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. European Journal of Endocrinology, 2013, 169, 263-270.	3.7	118
80	Sunitinib in Refractory Adrenocortical Carcinoma: A Phase II, Single-Arm, Open-Label Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3495-3503.	3.6	146
81	Localization of deformable tumors from shortâ€arc projections using Bayesian estimation. Medical Physics, 2012, 39, 7205-7214.	3.0	2
82	Combination Chemotherapy in Advanced Adrenocortical Carcinoma. New England Journal of Medicine, 2012, 366, 2189-2197.	27.0	692
83	Adrenocortical carcinoma: a clinician's update. Nature Reviews Endocrinology, 2011, 7, 323-335.	9.6	336
84	Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endocrinology, 2011, 75, 585-591.	2.4	110
85	Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma. European Journal of Endocrinology, 2010, 162, 349-356.	3.7	119
86	A Novel Syndrome of Mandibular Hypoplasia, Deafness, and Progeroid Features Associated with Lipodystrophy, Undescended Testes, and Male Hypogonadism. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E192-E197.	3.6	56
87	Deficits in the Management of Patients With Adrenocortical Carcinoma in Germany. Deutsches Ärzteblatt International, 2010, 107, 885-91.	0.9	44
88	Survival of Patients with Adrenocortical Carcinoma (ACC) after Radical Resection Revisited.. , 2010, , P3-78-P3-78.		0
89	Native purification of protein and RNA-protein complexes using a novel affinity procedure. Fly, 2009, 3, 223-231.	1.7	10
90	Evolution of an RNP assembly system: A minimal SMN complex facilitates formation of UsnRNPs in Drosophila melanogaster. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10045-10050.	7.1	92

#	Article	IF	Citations
91	Tdrd3 is a novel stress granule-associated protein interacting with the Fragile-X syndrome protein FMRP. Human Molecular Genetics, 2008, 17, 3236-3246.	2.9	77
92	Transporter regulator RS1 (RSC1A1) coats thetrans-Golgi network and migrates into the nucleus. American Journal of Physiology - Renal Physiology, 2006, 291, F1201-F1212.	2.7	28